A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension

A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is characterised by progressive pulmonary vascular remodelling. Here, Arnold et al. develop a therapeutic antibody targeting osteoprotegerin and find it attenuates pulmonary vascular remodelling in multiple rodent models of PAH, alone or in combination with stan...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nadine D. Arnold, Josephine A. Pickworth, Laura E. West, Sarah Dawson, Joana A. Carvalho, Helen Casbolt, Adam T. Braithwaite, James Iremonger, Lewis Renshall, Volker Germaschewski, Matthew McCourt, Philip Bland-Ward, Hager Kowash, Abdul G. Hameed, Alexander M. K. Rothman, Maria G. Frid, A. A. Roger Thompson, Holly R. Evans, Mark Southwood, Nicholas W. Morrell, David C. Crossman, Moira K. B. Whyte, Kurt R. Stenmark, Christopher M. Newman, David G. Kiely, Sheila E. Francis, Allan Lawrie
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/fbbe9cf6fb44471db21ebf04ce2094b6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Pulmonary arterial hypertension (PAH) is characterised by progressive pulmonary vascular remodelling. Here, Arnold et al. develop a therapeutic antibody targeting osteoprotegerin and find it attenuates pulmonary vascular remodelling in multiple rodent models of PAH, alone or in combination with standard of care vasodilator therapy.

Ejemplares similares